If you are a dog or a cat or a hamster owner and used to track news which is related to pet nutrition, pharmacy, and services, you should put some attention on the companies below. Since they are public companies you can buy their shares and gain some profit. Just because you may know a bit more than most traders.
Merck is a global pharmaceuticals, vaccines and animal health company with large pet division. In 2018 it managed to generate revenue of more than $42 billion.
The company has a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for its current-year earnings has moved up 1.9% over the past 60 days.
Tractor Supply is widely represented by retail stores in rural America. The company offers a selection of merchandise, including equine, livestock, pet, and small animal products. The company also owns Petsense, a small-box pet specialty supply retailer. There are almost 176 Petsense stores in 26 states in the U.S.
The company has a Zacks Rank #2 (Buy).
Chewy, Inc. operates as an online pet retailer. The Company offers pet products which include dry and wet food, toys, mats, biscuits, vitamins, and supplements. Chewy markets its products in North America.
Zacks’ proprietary data indicates that Chewy Inc. is currently rated as a Zacks Rank #2 (Buy).
IDEXX Laboratories, Inc. is known for selling diagnostic machines to vets that have given the company long-term recurring revenues.
The company has a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for its current-year earnings has moved 2.8% north over the past 60 days. The company, which is part of the Medical – Instruments industry, is expected to register earnings growth of 10.5% and 13.2% in the next quarter and current year, respectively.
As a healthcare company, CVS also offers some pet foods, toys, and grooming tools in its retail stores and online. Its revenue rose by 5.3% to $194.6 billion in 2018. The company’s 52-week range of its stock is $51.77 to $82.15 and provides a dividend yield of 3.5%.
The company has a Zacks Rank #3 (Hold).
CFRA analyst Kevin Huang rates the stock as a “strong buy” and wrote in his report that the shares are undervalued. His price target is $77 and anticipates that 2019 sales increase to $252 due to its acquisition of Aetna.
